Fundraising FoxVersant Ventures — 2025 Investments
5 investments dated 2025 · listed companies and verified rows first · show all
Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations.
BiotechDeep TechSouth San Francisco, US
Greg Lazar, Ph.D.(Co-Founder and Chief Scientific Officer)Forbes Huang(Co-Founder, Chief Operating Officer & Chief Business Officer)inGreg Lazar(Co-Founder & Chief Scientific Officer)inRichard Murray(Executive Officer, Director)Karim Dabbagh(Chief Executive Officer, Board Member)in
BoardAlicia Levey(Director)
Co-investorsQiming Venture PartnersSV Health InvestorsAlexandriaDementia Discovery FundQiming HealthcareQiming Venture Partners USA
Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.
BiotechMedical DevicesBasel, CH
Patrick Loustau(President and Chief Executive Officer)in
Co-investorsNovartis Venture FundSanofi VenturesForbion
Enable Injections develops and manufactures enFuse, a wearable drug delivery device that delivers large volumes of pharmaceutical and biologic therapeutics subcutaneously for patients with chronic diseases.
BiotechHealthtechMedical DevicesCincinnati, US
Mike Hooven(Chairman, President and CEO)inTimothy Flaherty(Executive Officer)Simone Song(Director)Karen Robards(Director)Richard J D'Augustine(Director)Norman R. Weldon(Director)
Board seatBeckie Robertson· per SEC Form D · $30M raise · filed Jan 2026
Co-investorsAngel Physicians FundCincyTechLightship CapitalOhio Innovation FundMagnetar AI Ventures
Aprea Therapeutics is a biopharmaceutical company developing novel cancer therapies targeting DNA damage response pathways to treat solid tumors including ovarian, colorectal, prostate, and breast cancers.
BiotechDigital HealthMedical DevicesDoylestown, US
John P. Hamill(Executive Officer)inOren Gilad(Chief Executive Officer, President)in
BoardJean-Pierre Bizzari(Director)Gabriela Gruia(Director)Rifat Pamukcu(Director)Bernd Seizinger(Director)
Co-investors5AM VenturesHealthCapRobin Hood VenturesRosetta Capital Ltd.Soleus Capital
Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone.
BiotechHealthtechSouthbury, US
Kevin Russ(Chief Executive Officer)inPeter DiLaura(Chief Executive Officer and Board Director)inWaters Kellogg(Director)Lucas B. Turner(Director)Joshua Dotson(Director)Holger Koehler(Director)
Co-investorsLongitude CapitalOrbiMedWellington Management
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.